Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Arvelle Therapeutics GmbH
Headquarters: Basel, Switzerland
Website: N/A
Year Founded: 2019
Status: Acquired
BioCentury | Jun 21, 2023
Management Tracks
Kaufmann joins Kyowa Kirin
Plus: Tan joins Heritas and updates from Noema and Versameb
BioCentury | Jul 28, 2021
Finance
Lumira to invest $35M ‘bespoke’ fund with Italy’s Angelini as sole backer
Angelini Lumira Biosciences Fund will invest in CNS and rare disease therapies
BioCentury | Jul 9, 2021
Management Tracks
Borio joins CEPI as SAB member; plus Aeglea, Codiak, Nordic Nanovector, BioShin and more
Luciana Borio, the senior fellow for global health at the Council on Foreign Relations, became a member of the scientific advisory board at Coalition for Epidemic Preparedness Innovations (CEPI).
BioCentury | Jun 15, 2021
Management Tracks
Avila joins Atea as SVP of medical affairs; plus Werewolf, Senda, Aurion, Sigilon and more
Viral infections company Atea Pharmaceuticals Inc. (NASDAQ:AVIR) hired Claudio Avila as SVP of medical affairs. Avila joins from Gilead Sciences Inc. (NASDAQ:GILD), where he was executive director of
BioCentury | May 1, 2021
Deals
European translation sees more money but fewer start-ups in 2020
Academia remains the primary source of innovation, but industry spinouts rose in number last year
BioCentury | Mar 31, 2021
Regulation
March 31 Quick Takes: Basket of EU approvals includes MS, SMA drugs; plus Amarin, AbbVie, Cara-Vifor
The European Commission approved Kesimpta ofatumumab from Novartis AG (NYSE:NVS; SIX:NOVN) to treat relapsing forms of multiple sclerosis. The subcutaneously administered drug was originally
BioCentury | Mar 17, 2021
Management Tracks
High-profile departures at Sage, bluebird as Cloonan, Davidson depart; plus CBC Group, Turning Point, Agilent, Intercept, Centessa, Beam and more
Mike Cloonan will depart Sage Therapeutics Inc. (NASDAQ:SAGE) as COO May 3 to pursue a CEO post in biopharma. The news comes after Barry Greene took Sage’s top spot in December. The
BioCentury | Jan 4, 2021
Deals
Angelini adds registrational epilepsy program via $610M Arvelle takeout
Via its $960 million takeout of Swiss CNS play Arvelle, Angelini will gain European rights to a late-stage epilepsy program. The deal, which includes $610 million in cash up front and up to $350
BioCentury | Jul 2, 2020
Finance
SK becomes Korea’s third-largest public healthcare company after $800M IPO
BioCentury | May 28, 2020
Finance
May 27 Quick Takes: Atara raises $176M on back of MS data; plus Exscientia’s $60M C round, Geron, Silence, Arvelle, ViaCyte, Poxel, Accure, Tollys
Items per page:
1 - 10 of 16